# Jean‐François Baurain

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jean-francois-baurain/

## Facts

| Field | Value |
| --- | --- |
| Citations | 11,913 |
| Field | Immunotherapy and Immune Responses |
| h-index | 36 |
| i10-index | 81 |
| Last Known Institution | Cliniques Universitaires Saint-Luc |
| OpenAlex ID | https://openalex.org/A5028034211 |
| ORCID iD | 0000-0003-4876-4600 |
| Works | 275 |

## Researcher papers

- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/overall-survival-benefit-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor](https://scholariq.org/papers/characterization-of-an-antigen-that-is-recognized-on-a-melanoma-showing-partial/)
- [Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034](https://scholariq.org/papers/randomized-phase-ii-trial-of-erlotinib-versus-temozolomide-or-carmustine-in/)
- [Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial](https://scholariq.org/papers/durvalumab-plus-carboplatin-paclitaxel-followed-by-maintenance-durvalumab-with/)
- [Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/three-year-overall-survival-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases](https://scholariq.org/papers/neogenesis-of-lymphoid-structures-and-antibody-responses-occur-in-human-melanoma/)
- [Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma](https://scholariq.org/papers/stratified-phase-ii-trial-of-cetuximab-in-patients-with-recurrent-high-grade/)
- [Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/efficacy-and-safety-of-niraparib-in-patients-aged-65-years-and-older-with/)

## Researcher topics

- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [Cliniques Universitaires Saint-Luc](https://scholariq.org/institutions/cliniques-universitaires-saint-luc/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.